In an unexpected turn of events, the FDA has issued a "Refusal to File" letter regarding Moderna's mRNA-1010 influenza vaccine. Moderna, well-known for its contributions during the global pandemic, is now facing a significant setback.
The FDA's decision stems from a technicality: Moderna compared its mRNA vaccine to Fluarix, a standard flu vaccine, instead of a high-dose variant recommended for seniors. This is particularly surprising given that pharmaceutical companies typically collaborate closely with the FDA to design trials that meet regulatory standards. In fact, only 4% of trials receive such a refusal. Moderna asserts that the FDA had approved this trial design back in April 2024.
Interestingly, the rejection appears to be more ideological than based on scientific evidence. Notably, Dr. David Kaslow, head of the FDA's vaccine office, advocated for the review of the data but did not sign the rejection letter. Instead, it was signed by Dr. Vinay Prasad, who has faced controversy in the past.
Importance of Scientific Integrity in Medical Trials
Conducting medical trials is notoriously difficult and costly. Moderna enrolled over 40,000 participants for its study, comparing the mRNA-1010 vaccine with the approved Fluarix vaccine.
Moderna maintains that the FDA had agreed to its trial plan, which included using a standard-dose vaccine for participants aged 65 and older. In the realm of drug development, an agreement with the FDA is often considered a strong commitment, ensuring that the agency will review the results.
Dr. Stephen Hoge, president of Moderna, expressed astonishment that the FDA declined to review the study after previously discussing the trial's adequacy with the agency.
This unexpected refusal raises questions, especially given the ongoing challenges in vaccine development and the urgent need for effective flu vaccines.
Concerns Over Vaccine Development Direction
Recent actions by the Health and Human Services (HHS) department under Secretary Robert F. Kennedy Jr. suggest a growing aversion to vaccines, particularly mRNA technology. In August 2025, HHS canceled 22 mRNA projects valued at $500 million, claiming these vaccines were ineffective against respiratory infections.
While skepticism is essential in scientific review, the current stance appears to be a shift back to traditional vaccine methods that are slower and less adaptable. Current flu vaccines are often based on predictions made months in advance, leading to mismatches that reduce their effectiveness.
In contrast, mRNA technology allows for rapid adaptation to emerging viruses, making it a crucial tool in pandemic response.
Promising Developments Outside the U.S.
Despite the FDA's refusal, regulatory bodies in Europe, Canada, and Australia have accepted Moderna's vaccine for review. Moderna anticipates receiving its first approval in Europe soon and is also developing combination vaccines for both COVID-19 and the flu, which would significantly enhance public health efforts.
Data suggests that Moderna's vaccine shows superior efficacy compared to current standard-dose flu shots, particularly benefiting high-risk seniors. The ongoing flu season has been notably severe, emphasizing the urgent need for effective vaccination options.
As scientists prepare for future flu seasons, the pursuit of safe and effective vaccines remains vital for saving lives and improving public health outcomes.
